share_log

Goldman Sachs Maintains Buy on BrightSpring Health, Lowers Price Target to $18

Goldman Sachs Maintains Buy on BrightSpring Health, Lowers Price Target to $18

高盛維持對BrightSpring Health的買入評級,將價格目標下調至18美元。
Benzinga ·  08/09 23:39  · 評級/大行評級

Goldman Sachs analyst Jamie Perse maintains BrightSpring Health (NASDAQ:BTSG) with a Buy and lowers the price target from $21 to $18.

高盛分析師Jamie Perse認爲BrightSpring Health(納斯達克股票代碼:BTSG)值得買入並將目標價從21美元降至18美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論